CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNSP Stock Price Chart Interactive Chart >
CNSP Price/Volume Stats
| Current price | $3.03 | 52-week high | $41.40 |
| Prev. close | $4.05 | 52-week low | $2.87 |
| Day low | $2.87 | Volume | 122,005 |
| Day high | $4.05 | Avg. volume | 27,758 |
| 50-day MA | $5.65 | Dividend yield | N/A |
| 200-day MA | $7.96 | Market Cap | 40.45M |
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Latest CNSP News From Around the Web
Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
CNS Pharmaceuticals Announces Reverse Stock SplitCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET today. Beginning on November 29, 2022, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but |
Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 resultsCNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021. |
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended September 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. |
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMCNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the first patient in Europe has been enrolled and dosed in France in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning, traders! |
CNSP Price Returns
| 1-mo | -36.88% |
| 3-mo | -58.00% |
| 6-mo | -68.83% |
| 1-year | -90.98% |
| 3-year | -97.55% |
| 5-year | N/A |
| YTD | -85.62% |
| 2021 | -60.54% |
| 2020 | -54.94% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...